#Zhang Xinmin

[mckitterick]

Finally, some optimistic news:

Japanese flu drug "clearly effective" in treating coronavirus, says China.

Medical authorities in China have said a drug used in Japan to treat new strains of influenza appeared to be effective in coronavirus patients, Japanese media said on Wednesday.

Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday.

Patients who were given the medicine in Shenzhen turned negative for the virus after a median of four days after becoming positive, compared with a median of 11 days for those who were not treated with the drug, public broadcaster NHK said.

In addition, X-rays confirmed improvements in lung condition in about 91% of the patients who were treated with favipiravir, compared to 62% or those without the drug.

Fujifilm Toyama Chemical, which developed the drug – also known as Avigan – in 2014, has declined to comment on the claims.

A Japanese health ministry source suggested the drug was not as effective in people with more severe symptoms:

“We’ve given Avigan to 70 to 80 people, but it doesn’t seem to work that well when the virus has already multiplied,” the source told the Mainichi Shimbun.

More in the Guardian article: X

[lisestuff]

"It is very safe and clearly effective," said Zhang Xinmin,

Fujifilm Toyama developed the drug in 2014. It has been administered to coronavirus patients in Japan since February.

[secondopianonews]

Covid-19, Cina: "Un farmaco giapponese è chiaramente efficace"

Covid-19, Cina: "Un farmaco giapponese è chiaramente efficace".

Le autorità cinesi sostengono che un farmaco giapponese si è dimostrato “chiaramente efficace” nel trattamento di pazienti contagiati dal covid-19.

Zhang Xinmin, dirigente del ministero cinese della Tecnologia e della Scienza, secondo il britannico “The Guardian” ha evidenziato i risultati ottenuti grazie all’impiego del Favipiravir, farmaco sviluppato da una controllata della Fujifilm.

Il…

[briefnewschannel]

The young “lie flat” as China’s growth model begins to fray

The young “lie flat” as China’s growth model begins to fray

Chinese politics & policy updates Sign up to myFT Daily Digest to be the first to know about Chinese politics & policy news. China’s social contract is fraying, and a song deleted from the country’s internet captures the problem vividly. “Lying flat is good, Lying flat is wonderful, Lying flat is right, Lie down so you don’t fall,” Zhang Xinmin sings in Chinese as he lies on a sofa strumming a…

[eagle-eyez]

Five years ago, Luo Huazhong discovered that he enjoyed doing nothing. He quit his job as a factory worker in China, biked 1,300 miles from Sichuan province to Tibet and decided he could get by on odd jobs and $60 a month from his savings. He called his new lifestyle “lying flat.”

“I have been chilling,” Luo, 31, wrote in a blog post in April, describing his way of life. “I don’t feel like there’s anything wrong.”

He titled his post “Lying Flat Is Justice,” attaching a photo of himself lying on his bed in a dark room with the curtains drawn. Before long, the post was being celebrated by Chinese millennials as an anti-consumerist manifesto. “Lying flat” went viral and has since become a broader statement about Chinese society.

A generation ago, the route to success in China was to work hard, get married and have children. The country’s authoritarianism was seen as a fair trade-off as millions were lifted out of poverty. But with employees working longer hours and housing prices rising faster than incomes, many young Chinese fear they will be the first generation not to do better than their parents.

They are now defying the country’s long-held prosperity narrative by refusing to participate in it.

Luo’s blog post was removed by censors, who saw it as affront to Beijing’s economic ambitions. Mentions of “lying flat” — tangping, as it is known in Mandarin — are heavily restricted on the Chinese internet. An official counternarrative has also emerged, encouraging young people to work hard for the sake of the country’s future.

“After working for so long, I just felt numb, like a machine,” Luo said in an interview. “And so I resigned.”

To lie flat means to forgo marriage, not have children, stay unemployed and eschew material wants such as a house or a car. It is the opposite of what China’s leaders have asked of their people. But that did not bother Leon Ding.

Ding, 22, has been lying flat for almost three months and thinks of the act as “silent resistance.” He dropped out of a university in his final year in March because he did not like the computer science major his parents had chosen for him.

After leaving school, Ding used his savings to rent a room in Shenzhen. He tried to find a regular office job but realized that most positions required him to work long hours. “I want a stable job that allows me to have my own time to relax, but where can I find it?” he said.

Ding thinks young people should work hard for what they love, but not “996” — 9 a.m. to 9 p.m., six days a week — as many employers in China expect. Frustrated with the job search, he decided that “lying flat” was the way to go.

“To be honest, it feels really comfortable,” he said. “I don’t want to be too hard on myself.”

To make ends meet, Ding gets paid to play video games and has minimized his spending by doing things like cutting out his favorite bubble tea. Asked about his long-term plans, he said, “Come back and ask me in six months. I only plan for six months.”

While plenty of Chinese millennials continue to adhere to the country’s traditional work ethic, “lying flat” reflects both a nascent counterculture movement and a backlash against China’s hypercompetitive work environment.

Xiang Biao, a professor of social anthropology at Oxford University who focuses on Chinese society, called tangping culture a turning point for China. “Young people feel a kind of pressure that they cannot explain, and they feel that promises were broken,” he said. “People realize that material betterment is no longer the single most important source of meaning in life.”

The ruling Communist Party, wary of any form of social instability, has targeted the “lying flat” idea as a threat to stability in China. Censors have deleted a tangping group with more than 9,000 members on Douban, a popular internet forum. Authorities also barred posts on another tangping forum with more than 200,000 members.

In May, China’s internet regulator ordered online platforms to “strictly restrict” new posts on tangping, according to a directive obtained by The New York Times. A second directive required e-commerce platforms to stop selling clothes, phone cases and other merchandise branded with “tangping.”

The state news media has called tangping “shameful,” and a newspaper warned against “lying flat before getting rich.” Yu Minhong, a prominent billionaire, urged young people not to lie down, because “otherwise, who can we rely on for the future of our country?”

Luo decided to write about tangping after he saw people heatedly discussing China’s latest census results in April and calls for the country to address a looming demographic crisis by having more babies.

He described his original “lying flat” blog post as “an inner monologue from a man living at the bottom of the society.”

“Those people who say lying down is shameful are shameless,” he said. “I have the right to choose a slow lifestyle. I didn’t do anything destructive to society. Do we have to work 12 hours a day in a sweatshop, and is that justice?”

Luo was born in rural Jiande County, in eastern Zhejiang province. In 2007, he dropped out of a vocational high school and started working in factories. One job involved working 12-hour shifts at a tire factory. By the end of the day, he had blisters all over his feet, he said.

In 2014, he found a job as a product inspector in a factory but did not like it. He quit after two years and took on the occasional acting gig to make ends meet. (In 2018, he played a corpse in a Chinese movie by, of course, lying flat.)

Today, he lives with his family and spends his days reading philosophy and news and working out. He said it was an ideal lifestyle, allowing him to live minimally and “think and express freely.” He encourages his followers, who call him “the Master of Lying Down,” to do the same.

(STORY CAN END HERE. OPTIONAL MATERIAL FOLLOWS.)

After hearing about Luo’s tangping post on a Chinese podcast, Zhang Xinmin, 36, was inspired to write a song about it.

Zhang, a musician based in Wuhan, had quit his job in advertising five years ago to pursue his music, and the idea of lying flat resonated with him. He called his song “Tangping Is the Right Way.”

Zhang uploaded the song to his social media platforms June 3, and within a day censors had deleted it from three websites. He was furious.

“Nowadays, only running forward is allowed, but not lying down,” he said. “It doesn’t make sense to me that they deleted this song.”

He eventually uploaded the song as a video on YouTube, which is blocked in China. The video shows him lying down on his sofa, casually strumming his guitar as he sings in a breezy voice:

Lying down is really goodLying down is wonderfulLying down is the right thing to doLie down so you won’t fall anymoreLying down means never falling down.

This article originally appeared in The New York Times.

from Firstpost World Latest News https://ift.tt/3xtoJBa

[multimediosnoxsalta]

China contará con 610 millones de dosis de vacunas anti-Covid-19 en 2020 y 1.000 millones en 2021.

China prevé fabricar 610 millones de dosis de la vacuna del coronavirus antes de que acabe este año y 1.000 millones en 2021, aseguró hoy el director del Centro de Desarrollo de Ciencia y Tecnología de la Comisión Nacional de Salud, Zheng Zhongwei. En una rueda de prensa, Zheng dijo en Beijing que 11 vacunas de cinco compañías con participación del país están en la fase 3 de ensayos clínicos sin haber mostrado efectos adversos y agregó que esperan poder aplicarla masivamente "lo antes posible". Señaló que las llamadas vacunas de emergencia, que China comenzó a aplicar el pasado julio, se han utilizado en "grupos de riesgo" y han presentado resultados "muy sólidos". "Hemos tenido un mecanismo muy estricto para verificar cualquier reacción adversa para todos los que han participado en el proceso. Ningún caso adverso se detectó", recalcó, citado por la agencia de noticias EFE. Por su parte, el director del centro biológico del Ministerio de Ciencia y Tecnología, Zhang Xinmin, explicó en la misma conferencia de prensa que hasta cierto punto es "normal y aceptable" que las vacunas en pruebas puedan presentar algunos efectos adversos. "Algunas, como las del dengue, lo hicieron, pero en este caso no ha ocurrido. No obstante, se necesita más tiempo de observación hasta poder dar por concluidas las pruebas de la fase 3", la última de ensayos clínicos. Read the full article

[apicdmo]

COVID-2019: Status of Favipiravir in the world

 ❶ China says: “Antiviral favipiravir effective against COVID-19”

 Randomized trials of the broad-spectrum antiviral favipiravir, marketed as an anti-influenza treatment, have shown "obvious efficacy" against COVID-19, according to Zhang Xinmin, head of the China National Center for Biotechnology Development. Zhang's comments were reported by Xinhua News Agency, China's official state-run press agency.

 In one trial, testing favipiravir with interferon in Shenzhen, results showed that patients treated with the combination had significantly reduced the duration of symptoms, as measured by viral load chest imaging, vs. a control group. In another study, clinical recovery rates were higher for COVID-19 patients treated with favipiravir vs. those in a control group.

 ❷ Russia says: “Favipiravir(Avifavir) has been approved to treat COVID-2019”

 Russia has approved an anti-influenza drug, Favipiravir, to treat Covid-19 and will start delivering it to hospitals this month, according to Russia’s sovereign wealth fund.

 Preliminary trials appeared to show that it could shorten recovery times for patients with Covid-19. The final stage of Favipiravir clinical trials involving 330 patients are ongoing, RDIF and ChemRar said Monday, but patients are ongoing, RDIF and ChemRar said Monday, but Russia’s Ministry of Health on Saturday already temporarily approved the use of the drug as a coronavirus treatment.

 favipiravir is Russia’s first Covid-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. favipiravir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, favipiravir has become the first Favipiravir-based drug in the world approved for the treatment of Covid-19,” they said in the statement.

 ❸ India says: "Glenmark Pharmaceuticals has gained an approval from India’s drug regulator for the antiviral drug favipiravir for the treatment of mild-to-moderate COVID-19 patients."

 Glenmark Pharmaceuticals has gained an approval from India’s drug regulator for the antiviral drug favipiravir for the treatment of mild-to-moderate COVID-19 patients.Glenmark is now set to manufacture and market its favipiravir product under the brand name FabiFlu in India, and is the first oral favipiravir-approved medication in the country for the treatment of COVID-19.

 The approval is based on clinical evidence of favipiravir demonstrating promising results in patients with mild-to-moderate COVID-19 disease. According to Glenmark, the drug offers rapid reduction in viral load with four days and provides faster symptomatic and radiological improvement. In addition, favipiravir demonstrated clinical improvement of up to 88% among those with a mild-to-moderate case of COVID-19.“FabiFlu has demonstrated an encouraging response in mild-to-moderate COVID-19 patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications,” said Saldanha.

 Glenmark has also announced its intention to conduct another clinical trial to evaluate the efficacy of favipiravir and another antiviral drug, umifenovir, as a combination therapy in moderate, hospitalised adult COVID-19 patients in India.

 ❹ Attitudes from more countries on against COVID-2019 by Favipiravir

 The US Department of Defense developed favipiravir in partnership with MediVector, Inc. as a broad-spectrum antiviral and sponsored it through FDA Phase II and Phase III clinical trials, where it demonstrated safety in humans and efficacy against the influenza virus.Despite demonstrating safety in more than 2,000 patients and showing accelerated clearance of influenza virus by 6 to 14 hours in the Phase III trials, favipiravir remains unapproved in the UK and the USA.

 The Italian Pharmaceuticals Agency AIFA has approved testing antiviral drug favipiravir for the coronavirus, Health Minister Roberto Speranza said on Monday. The technical-scientific committee is developing a testing and research programme to assess the impact of the drug in the initial phases of the disease after an initial analysis of the available data on favipiravir.

https://www.apicdmo.com/product/259793-96-9/

[zuytcom]

Bất chấp ‘làn sóng virus thứ hai’, dân Trung Quốc thản nhiên vui chơi

Thứ Ba, 07/04/2020 lúc 3:38

Trung Quốc đang đối mặt với ‘làn sóng thứ hai’ của dịch Covid-19, tuy nhiên nhiều người vẫn chủ quan đi chơi, du lịch sau khi nhiều địa phương nới lỏng các biện pháp cách ly.

Công viên núi Hoàng Sơn thuộc tỉnh An Huy hôm 4/4 chật kín khách du lịch bất chấp nguy cơ Trung Quốc có thể hứng chịu “làn sóng virus thứ hai”. Ảnh: CNN.

“Thật vội vã khi mọi người chen chúc đến các điểm vui chơi như vậy”, CNN trích dẫn nhận định từ một tờ báo địa phương. Có tới 20.000 lượt khách đến tham quan công viên này mỗi ngày, buộc ban quản lý phải dừng việc tiếp nhận thêm khách du lịch. Ảnh: Sohu.

Tình trạng tương tự cũng xảy ra ở thủ đô Bắc Kinh khi người dân đổ xô đến các công viên và địa điểm vui chơi của thành phố dịp lễ Thanh Minh. Ảnh: CNN.

Hình ảnh được ghi lại hôm 5/4 tại một trung tâm mua sắm ở Bắc Kinh. Ảnh: Zhang Yanzheng.

Bên trong một cửa hàng ăn uống tại Bắc Kinh hôm 5/4. Ảnh: Zhang Yanzheng.

Người tiêu dùng xếp hàng đông đúc trước một cửa hàng Gucci ở Bắc Kinh. Ảnh: Zhang Yanzheng.

Theo phóng viên địa phương, tính đến 7 giờ sáng ngày 6/4, 10.000 vé tham quan tại Cung điện mùa hè Bắc Kinh đã được bán hết. Ngoài ra, 8.892 vé đã được bán cho ngày 7/4 và hơn 9.800 vé cũng được đặt mua cho các chuyến tham quan ngày 8-11/4. Ảnh: Flickr.

Các gia đình đi cắm trại tại bãi cỏ trong Công viên Thế kỷ tại Thượng Hải dịp lễ Thanh Minh. Ảnh: Jin Minyun/Xinmin Evening News.

Hình ảnh tại công viên ở thành phố Kim Hoa, tỉnh Chiết Giang. Ảnh: Tân Hoa Xã.

Điểm bán vé tại phố cổ Chu Trang, tỉnh Giang Tô. Ảnh: Tân Hoa Xã.

Một địa điểm du lịch tại thị trấn Kiến Hoa thuộc tỉnh Hắc Long Giang. Từ ngày 4-5/4, tổng cộng khoảng 1.000 phòng đã được khách du lịch thuê tại đây. Ảnh: Tân Hoa Xã.

Hương Giang

!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0'; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,'script', 'https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '907774919272108'); fbq('track', 'PageView');

Bài viết Bất chấp ‘làn sóng virus thứ hai’, dân Trung Quốc thản nhiên vui chơi đã xuất hiện đầu tiên vào ngày Zuyt.

from Zuyt https://zuyt.com/kham-pha/bat-chap-lan-song-virus-thu-hai-dan-trung-quoc-than-nhien-vui-choi/

[pharmaphorumuk]

Gilead halts ‘compassionate use’ of potential coronavirus drug

Gilead has said it has stopped accepting “compassionate use” requests for its potential coronavirus antiviral remdesivir because it cannot keep pace with demand as health systems become overwhelmed.

Remdesivir is seen as the best hope in the fight against the COVID-19 coronavirus, at least until a vaccine comes along and several trials are already under way.

But the US pharma said that it is facing huge demand for compassionate use requests for the drug, where the drug is given to severely ill patients as there are no approved treatment options that are effective.

California-based Gilead said there has been an “exponential increase” in compassionate use requests as the SARS-CoV-2 virus spreads across Europe and the US.

As a result this has “flooded” an emergency treatment access system set for very limited access to investigational drugs, and was never intended for use in response to a pandemic.

In response Gilead said it is moving existing individual compassionate use requests to an “expanded access” programme.

This will ensure these requests are met with a similar 72-hour timeframe to the compassionate use requests.

But the company will not accept new compassionate use requests, except for pregnant women and children aged under 18 with confirmed COVID-19 and severe symptoms.

Latest figures from the World Health Organization show the virus is still spreading rapidly throughout Europe and the US.

The data published on Sunday show 53,578 new cases in Italy, with 6,557 new cases, 4,827 deaths, and 795 new deaths.

Spain is badly hit with nearly 25,000 cases, 1,326 deaths, and 324 new deaths. In the US there are 15,219 cases, 201 deaths, but figures show no new cases or new deaths.

In China there are more than 81,000 confirmed cases, with 82 confirmed new cases and six new deaths, with 3,267 total deaths.

Gilead’s share price was down in premarket trading following the news, falling by more than $5, almost 7%, following the announcement.

Medical authorities in China last week said that a similar drug, favipiravir, developed to treat new strains of influenza appeared to be effective in coronavirus patients.

The Guardian reported that Zhang Xinmin, an official at China’s science and technology ministry said favipiravir had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients.

The post Gilead halts ‘compassionate use’ of potential coronavirus drug appeared first on .

from https://pharmaphorum.com/news/gilead-halts-compassionate-use-of-potential-coronavirus-drug/

[frontedelblog]

Coronavirus, la verità sul "miracoloso" farmaco giapponese Avigan (direttamente dal Giappone)

Non è vero che in Giappone girano tranquilli perché utilizzano Avigan: la sperimentazione è cinese, e nel Paese del Sol Levante lo stanno testando per ora utilizzato su 80 persone. E allora perché girano serenamente per strada? Ecco ciò che accade   Di Edoardo Montolli La notizia di un farmaco giapponese quasi miracoloso contro il coronavirus, l’Avigan, ha fatto presto il giro del web, dei giornali e delle istituzioni. Tutto nasce da due video che un giovane italiano, Cris Ares, ha postato su Facebook dal Giappone: si vede molta gente in giro, nelle piazze, davanti ai locali, a volte letteralmente assembrata. Riporta Repubblica: Cristiano Aresu, 41 anni, che per lavoro va spesso nel paese del Sol Levante, ha postato video su Facebook di ciò che accade a Tokyo, impazzando sui social. “L’Avigan è un antinfluenzale fino a poco tempo fa venduto in farmacia: qui hanno scoperto che somministrato ai primi sintomi di coronavirus, accertati con il tampone, blocca il progredire della malattia nel 91% dei casi”, racconta Aresu nel video dando per scontate e reali le potenzialità del farmaco che sono invece tutte da dimostrare. La gente spaventata e in cerca di una soluzione sta condividendo il video a ritmi vorticosi. Il medicinale di cui si parla nel video di Facebook si chiama Favipiravir ma tra i non addetti è meglio noto con il nome di Avigan. Si tratta di un farmaco antivirale sviluppato nel 2014 dal gruppo giapponese Fujifilm Toyama Chemical (una consociata di Fujifilm) e che in questi giorni, a quanto pare, si sta rivelando una manna dal cielo per curare i pazienti affetti da Covid-19.   Il Veneto ha deciso di sperimentarlo subito: L’Aifa ha rilasciato una nota di precisazione: Favipiravir (nome commerciale Avigan) è un antivirale autorizzato in Giappone dal Marzo 2014 per il trattamento di forme di influenza causate da virus influenzali nuovi o riemergenti e il suo utilizzo è limitato ai casi in cui gli altri antivirali sono inefficaci. Il medicinale non è autorizzato né in Europa, né negli USA. Ad oggi, non esistono studi clinici pubblicati relativi all’efficacia e alla sicurezza del farmaco nel trattamento della malattia da COVID-19. Sono unicamente noti dati preliminari, disponibili attualmente solo come versione pre-proof (cioè non ancora sottoposti a revisione di esperti), di un piccolo studio non randomizzato, condotto in pazienti con COVID-19 non grave con non più di 7 giorni di insorgenza, in cui il medicinale favipiravir è stato confrontato all’antivirale lopinavir/ritonavir (anch’esso non autorizzato per il trattamento della malattia COVID-19), in aggiunta, in entrambi i casi, a interferone alfa-1b per via aersol. Sebbene i dati disponibili sembrino suggerire una potenziale attività di favipiravir, in particolare per quanto riguarda la velocità di scomparsa del virus dal sangue e su alcuni aspetti radiologici, mancano dati sulla reale efficacia nell’uso clinico e sulla evoluzione della malattia. Gli stessi autori riportano come limitazioni dello studio che la relazione tra titolo virale e prognosi clinica non è stata ben chiarita e che, non trattandosi di uno studio clinico controllato, ci potrebbero essere inevitabili distorsioni di selezione nel reclutamento dei pazienti. La Commissione Tecnico-Scientifica di AIFA, riunita in seduta permanente, rivaluta quotidianamente tutte le evidenze che si rendono disponibili al fine di poter intraprendere ogni azione (inclusa l’autorizzazione rapida alla conduzione di studi clinici) per poter assicurare tempestivamente le migliori opzioni terapeutiche per il COVID-19 sulla base di solidi dati scientifici. In particolare, nella seduta di domani, lunedì 23 marzo, la Commissione si esprimerà in modo più approfondito rispetto alle evidenze disponibili per il medicinale favipiravir. Si ribadisce che AIFA è costantemente impegnata a tutelare la salute pubblica, a maggior ragione in un momento di emergenza come quello attuale, dando informazioni puntuali e aggiornate sulle evidenze scientifiche e, nell’esortare a non dare credito a notizie false e a pericolose illazioni, si riserva il diritto di adire a vie legali ove opportuno.     IL GIAPPONE SPERIMENTA La cosa, va da sè, incuriosisce. E vale la pena dare un’occhiata ai media giapponesi. Al 22 marzo, precisiamolo subito, in Giappone c’erano 1101 persone contagiate, cui aggiungere attualmente 712 persone di una nave da crociera. A Tokyo, alla stessa data, dove sarebbe stato girato secondo Repubblica almeno uno dei video, gli infetti erano 138, non proprio un'enormità. I decessi totali sono 47, per un tasso di mortalità del 4,2%, assai più basso del nostro. Ma come abbiamo spiegato ieri, secondo gli studi cinesi del 24 febbraio scorso, la mortalità provocata dal coronavirus dipende dall’intensità di trasmissione, ovvero dalla densità e dalla velocità con cui si propaga. Cosa che noi abbiamo consentito più di chiunque altro, trattandola a lungo in maniera demenziale come un'influenza. Avigan   La domanda però  è: davvero in Giappone vanno tutti in giro serenamente perché si sentono protetti dall’Avigan? La risposta, purtroppo, è no. Basta dare un’occhiata al sito della Nippon Hōsō Kyōkai, o NHK, la tv di Stato giapponese. Proprio ieri 22 marzo era riportato un articolo sull’uso di un loro farmaco, l’Avigan, in Cina. Vi si precisa che il Giappone ha deciso ora di iniziare una sperimentazione su 80 persone al Fujita Medical University Hospital nella prefettura di Aichi, dopo i risultati di uno studio clinico fatto in Cina. In sostanza sono sorpresi quanto noi dai primi risvolti positivi di un medicinale usato contro l’influenza ma non particolarmente usato perché erano stati segnalati effetti collaterali sui feti nelle donne in gravidanza. I risultati dello studio cinese sull’Avigan sono stati infatti divulgati in Giappone solo recentemente. NHK ne parla il 17 marzo, raccontando della conferenza stampa tenuta a Pechino da Zhang Xinmin, capo del Centro biologico del Ministero della Scienza e della Tecnologia. Il farmaco, sostiene Zhang «ha dimostrato di avere un effetto terapeutico sulla polmonite e altre malattie causate dal nuovo coronavirus e non sono stati osservati effetti collaterali evidenti». Lo studio è stato fatto in alcuni istituti di Wuhan e a Shenzhen, nella provincia del Guangdong, rispettivamente su 240 e 80 pazienti. Il coronavirus si sarebbe negativizzato in 4 giorni anzichè in 11 e l’Avigan avrebbe portato a miglioramenti nel 91% dei casi, al momento su un campione che appare molto ridotto. Ma incoraggiante. Tanto che ora una società farmaceutica cinese lo produrrà grazie ad una licenza concessa dalla società produttrice di Avigan. In Giappone, dunque, non vi è al momento nessuna certezza. Il dottor Shirano di Osaka Ma le stesse speranze che nutriamo noi da una sperimentazione. Tanto che al centro medico municipale di Osaka, reparto malattie infettive, il dottor Shirano ha iniziato a usare Avigan, in alternativa al Kaletra (farmaco usato nel trattamento dell’hiv) su alcuni dei 20 pazienti che ha in cura. Ad oggi, ad Osaka, ci sono 131 infetti. Le sue osservazioni sono le stesse dei medici italiani: «Le persone anziane, quelle con malattie croniche del cuore e dei polmoni, quelle con diabete e ipertensione arteriosa sembrano essere più gravemente colpite e possono improvvisamente ammalarsi». Devono dunque fare attenzione. Poi, l’avvertimento (che ben conosciamo): «Quando aumenta il numero di persone infette e aumenta il numero di pazienti gravemente malati negli ospedali, vengono raggiunti i limiti di personale e strutture». LA CULTURA GIAPPONESE Eppure, nei video diventati virali su Facebook, noi possiamo notare molta gente in giro per le strade anche se non è affatto vero che girino tutte senza mascherina, come possiamo vedere in alcuni dei frame dei video qui sotto. Ne abbiamo presi solo alcuni:   E allora perché ci si contagia meno e in quello che è il Paese più anziano del mondo (l’Italia è al secondo posto) non vi è tutto questo terrore? Perchè alcuni indossano una mascherina e altri no? Ecco quanto ci ha detto una donna giapponese che vive in Italia da trent’anni, ma la cui famiglia d’origine sta vivendo l’emergenza coronavirus in Giappone: «Si tratta di un problema culturale. In Giappone non c’è l’abitudine di baciarsi e abbracciarsi come in Italia. Soprattutto, specie in questo periodo dell’anno, è consuetudine che chi ha anche solo un raffreddore indossi la mascherina, per evitare di contagiare gli altri. Per rispetto. Per questo la gente gira tranquilla: perché  sa che chi  ha anche solo un raffreddore  protegge gli altri coprendosi». Ecco perché i contagi non sono così tanti. «Il nostro è un Paese molto prudente. E attento alla salute. La sanità è ai primi posti, tanto che abbiamo 13 posti letto d’ospedale ogni mille abitanti». L’Italia, tra pubblico e privato, ne ha 3,2 ogni mille. Edoardo Montolli Gli ultimi libri di Edoardo Montolli ** SPECIALE CORONAVIRUS – GUARDA ** Read the full article

[udoudochukwu]

China has said that a Japanese flu drug is 'clearly effective' in clinical trials on coronavirus patients

China has said that a Japanese flu drug is ‘clearly effective’ in clinical trials on coronavirus patients

Medical authorities in China have said that a Japanese drug, favipiravir also known as, T-705, which is used in the country (Japan) to treat new traces of influenza seems to be effective in patients of coronavirus, the Guardian reports that Japanese media said on Wednesday.

A Chinises authority at its science and technology ministry, Zhang Xinmin, disclosed that the drug developed by a…

[utrechtcentral]

Treatment found to be effective for treating Coronavirus

Just found out through a friend on Facebook that Chinese officials can confirm that Japanese officials have found an antiviral drug to be effective in treating the coronavirus in its early stages. Now that's a lot of officials! This news comes undoubtedly as a new hope for groups and individuals who feel they are being overwhelmed with hopelessness in line with recent events around the coronavirus. The drug is called Favipiravir, which was originally created by a subsidiary firm of Fujifilm, was initially intended as a treatment for the flu. The drug is believed to work by selectively locating and disrupting the DNA strands present in active coronavirus cells making them virtually unable to carry out their mission of chaos in human lungs. Studies carried out by a number of medical authorities in China have resulted in a number of positive scenarios. Those administered the drug tested negative for the virus four days later on average. Additionally, in approximately 91 percent of patients who received Favipiravir, X-rays indicated positive changes in patients lungs compared to those who did not receive the drug. Zhang Xinmin, a spokesperson at China’s science and technology ministry confirmed that the drug has a high degree of safety and is clearly effective in treatment. Well there you have it, in this closely connected world, the solutions are surfacing faster than we could imagine. What a great age to live in! Is there any WiFi here? 😄 Sources: My new Thai friend on Facebook and The Guardian and Wikipedia.

Read the full article

[farry]

Obat Flu Merk Avigan Buatan Fujifilm Jepang Efektif Lawan Virus Corona Repost @neng_jepret ••• Jepang - China menyebut obat flu bernama FAVIPIRAVIR yang dijual dengan merk AVIGAN buatan Fujifilm Toyama Chemicals, efektif mengobati pasien virus Corona . Pemerintah China pun merekomendasikan obat tersebut . "Obat ini sangat aman dan efektif dan tidak ada efek samping,” kata Zhang Xinmin, Direktur Pusat Pengembangan Bioteknologi Tiongkok, seperti dikutip Nikkei Asian Review, Rabu (18/3) . Fujifilm Toyama mengembangkan obat tersebut pada 2014 dan sejak Februari 2020 telah diberikan kepada pasien Covid-19 di Jepang . Sedangkan ujicoba obat FAVIPIRAVIR secara klinis terhadap 200 orang pasien di Wuhan dan Shenzen menunjukkan pasien yang menerima obat tersebut langsung dikonfirmasi negatif Covid-19 hanya dalam waktu 4 hari Menurut Zhang, pasien yang memakai FAVIPIRAVIR dites negatif setelah 4 hari dan pengguna obat lain 11 hari . Sementara itu, dari percobaan klinis di Wuhan, pasien yang diobati FAVIPIRAVIR sembuh dari demam dalam 2,5 hari dan pasien lain 4 hari, gejala batuk membaik dalam 4 hari, lebih awal dibanding mereka yang tidak minum obat . AVIGAN sendiri, diatur khusus oleh pemerintah Jepang, di mana ia hanya bisa digunakan jika influenza jenis baru muncul . Pasalnya ada studi yang mengatakan ia rentan membuat kegagalan janin. Tapi hal ini tak dijelaskan Zhang . Dan kini China dikabarkan mulai memproduksi FAVIPIRAVIR secara serius. Namun Fujifilm mengatakan perusahaan tidak ikut dalam uji klinis itu . . . . . . Picture capture from NHK World @warung_jurnalis https://www.instagram.com/p/B95ySZ_gyXs/?igshid=5qruxnyktda8

[azhar607-blog]

FROM THE DESK OF DR TAHIR MD Tel: 5854815408 Web : http://totalhealthcarephysician.com/success-stories.html _______________________________________________ VERY GOOD NEWS : CORONA VIRUS TREATMENT FOUND IN CHINA . ___________________________________________ Zhang Xinmin, an official at China’s science and technology ministry, said favipiravir, developed by a subsidiary of Fujifilm, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen involving 340 patients. “It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters on Tuesday. https://www.theguardian.com/world/2020/mar/18/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china https://www.instagram.com/p/B95SxtZl_SE/?igshid=193s6ju3vrk2t

[superpte]

Treatment For SARS 2/COVID 19?... & Don't Take Ibuprofen/NSAID!

Treatment For SARS 2/COVID 19?… & Don’t Take Ibuprofen/NSAID!

Crowned Creation against the Crown of Creation:

A drug used to treat influenza seems to be effective at treating the novel coronavirus that causes COVID-19, according to news reports from Japan and China.

The antiviral drug, called Favipiravir or Avigan, showed positive outcomes in clinical trials involving 340 individuals in Wuhan and Shenzhen, said Zhang Xinmin, of China’s science and…